![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » ICER Forms Advisory Group to Analyze Rationale Behind Drug Price Hikes
ICER Forms Advisory Group to Analyze Rationale Behind Drug Price Hikes
July 2, 2018
The Institute for Clinical and Economic Review has formed an advisory group to evaluate whether clinical evidence supports prescription drug price hikes.
Several states have implemented laws to list drugs that are subject to major price hikes, but policymakers, patients and stakeholders “do not have access to a specific equation to determine which factors cause these price increases,” ICER said.
The institute will issue its initial annual report in the first quarter of next year. The company has assembled a 10-stakeholder advisory committee to develop the methodology for the report.
Upcoming Events
-
21Oct